CT-Based Radiomics Analysis to Predict Malignancy in Patients with Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas

被引:39
|
作者
Tobaly, David [1 ]
Santinha, Joao [2 ,3 ]
Sartoris, Riccardo [1 ,4 ]
Dioguardi Burgio, Marco [1 ,4 ]
Matos, Celso [5 ,6 ]
Cros, Jerome [7 ]
Couvelard, Anne [8 ]
Rebours, Vinciane [9 ]
Sauvanet, Alain [10 ]
Ronot, Maxime [1 ,4 ]
Papanikolaou, Nikolaos [11 ]
Vilgrain, Valerie [1 ,4 ]
机构
[1] Hop Beaujon, AP HP Nord, AP HP, Serv Radiol, F-92110 Clichy, France
[2] Champalimaud Fdn, Champalimaud Res, Computat Clin Imaging Grp, Ave Brasilia, P-1400038 Lisbon, Portugal
[3] Univ Lisbon, Inst Super Tecn, Inst Telecomunicacoes, P-1049001 Lisbon, Portugal
[4] Univ Paris, INSERM, U1149, Ctr Rech Inflammat Cri, F-75018 Paris, France
[5] Champalimaud Fdn, Radiol Dept, Ave Brasilia, P-1400038 Lisbon, Portugal
[6] Champalimaud Fdn, Champalimaud Res, Ave Brasilia, P-1400038 Lisbon, Portugal
[7] Hop Beaujon, AP HP Nord, AP HP, Serv Anatomopathol, F-92110 Clichy, France
[8] Hop Bichat Claude Bernard, AP HP Nord, AP HP, Serv Anatomopathol, F-75018 Paris, France
[9] Hop Beaujon, AP HP Nord, AP HP, Serv Pancreatol, F-92110 Clichy, France
[10] Hop Beaujon, AP HP Nord, AP HP, Serv Chirurg HPB, F-92110 Clichy, France
[11] Champalimaud Fdn, Champalimaud Res, Computat Clin Imaging Grp, P-1400038 Lisbon, Portugal
关键词
risk stratification; quantitative imaging; texture; malignant transformation; radiomics; pancreatic cyst; INTERNATIONAL CONSENSUS GUIDELINES; PHASE HELICAL CT; IMAGING FEATURES; MANAGEMENT; CYSTS; PERFORMANCE; PREVALENCE; DIAGNOSIS; SYSTEM;
D O I
10.3390/cancers12113089
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The management of intraductal papillary mucinous neoplasms of the pancreas (IPMN) remains controversial due to the relatively high rate of unnecessary surgery for low grade dysplasia (LGD) despite the last international recommendations. The aim of our retrospective study was to assess the performance of radiomic analysis on CT in differentiating benign from malignant IPMN. We confirmed in a training cohort (296 patients) and a validation cohort (112 patients) that a total of 85 radiomics features provided valuable additional and independent information for discriminating benign from malignant tumors in the training cohort with an area under the ROC curve (AUC) of 0.84 and an external validation with an AUC of 0.71 with higher performance when implementing clinical variables leading to the indication to surgery. We have demonstrated the capabilities of radiomics models comprising LGD versus high-grade dysplasia (HGD) versus invasive, LGD and HGD, HGD and invasive. To assess the performance of CT-based radiomics analysis in differentiating benign from malignant intraductal papillary mucinous neoplasms of the pancreas (IPMN), preoperative scans of 408 resected patients with IPMN were retrospectively analyzed. IPMNs were classified as benign (low-grade dysplasia, n = 181), or malignant (high grade, n = 128, and invasive, n = 99). Clinicobiological data were reported. Patients were divided into a training cohort (TC) of 296 patients and an external validation cohort (EVC) of 112 patients. After semi-automatic tumor segmentation, PyRadiomics was used to extract radiomics features. A multivariate model was developed using a logistic regression approach. In the training cohort, 85/107 radiomics features were significantly different between patients with benign and malignant IPMNs. Unsupervised clustering analysis revealed four distinct clusters of patients with similar radiomics features patterns with malignancy as the most significant association. The multivariate model differentiated benign from malignant tumors in TC with an area under the ROC curve (AUC) of 0.84, sensitivity (Se) of 0.82, specificity (Spe) of 0.74, and in EVC with an AUC of 0.71, Se of 0.69, Spe of 0.57. This large study confirms the high diagnostic performance of preoperative CT-based radiomics analysis to differentiate between benign from malignant IPMNs.
引用
收藏
页码:1 / 19
页数:19
相关论文
共 50 条
  • [41] Senescence in intraductal papillary mucinous neoplasm of the pancreas
    Miyasaka, Yoshihiro
    Nagai, Eishi
    Ohuchida, Kenoki
    Fujita, Hayato
    Nakata, Kohei
    Hayashi, Akifumi
    Mizumoto, Kazuhiro
    Tsuneyoshi, Masazumi
    Tanaka, Masao
    HUMAN PATHOLOGY, 2011, 42 (12) : 2010 - 2017
  • [42] Strategy in intraductal papillary mucinous neoplasm of the pancreas
    Navarro Colas, Salvador
    Vaquero Raya, Eva C.
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2012, 35 (09): : 652 - 659
  • [43] Intraductal Papillary Mucinous Neoplasm of the Pancreas: An Update
    Xiao, Shu-Yuan
    SCIENTIFICA, 2012, 2012
  • [44] A National Perspective of Invasive Intraductal Papillary Mucinous Neoplasm (IPMN)
    Lewis, Russell
    Drebin, Jeffrey
    Fraker, Douglas L.
    Vollmer, Charles M.
    GASTROENTEROLOGY, 2014, 146 (05) : S1048 - S1048
  • [45] Management of intraductal papillary mucinous neoplasm of the pancreas
    Masanori Sugiyama
    Yutaka Suzuki
    Nobutsugu Abe
    Toshiyuki Mori
    Yutaka Atomi
    Journal of Gastroenterology, 2008, 43 : 181 - 185
  • [46] Intraductal Papillary Mucinous Neoplasm (IPMN): A Precursor to Pancreatic Cancer
    Neesse, Albrecht
    Michl, Patrick
    Kalinowski, Marc
    Barth, Peter J.
    Bartsch, Detlef K.
    Ellenrieder, Volker
    Gress, Thomas M.
    CURRENT CANCER THERAPY REVIEWS, 2010, 6 (03) : 175 - 184
  • [47] Hereditary intraductal papillary mucinous neoplasm of the pancreas
    Denost, Q.
    Chafai, N.
    Arrive, L.
    Mourra, N.
    Paye, F.
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2012, 36 (02) : E23 - E25
  • [48] Intraductal papillary mucinous neoplasm of the pancreas (IPMN): clinico-pathological correlations and surgical indications
    Baiocchi, Gian Luca
    Portolani, Nazario
    Missale, Guido
    Baronchelli, Carla
    Gheza, Federico
    Cantu, Massimiliano
    Grazioli, Luigi
    Giulini, Stefano M.
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2010, 8
  • [49] ABO blood group distribution and risk of malignancy in patients undergoing resection for intraductal papillary mucinous neoplasm (IPMN)
    Zelga, Piotr
    Hernandez-Barco, Yasmin G.
    Qadan, Motaz
    Ferrone, Cristina R.
    Baba, Taisuke
    Bolm, Louisa
    Jah, Asif
    Warshaw, Andrew L.
    Lillemoe, Keith D.
    Balakrishnan, Anita
    Fernandez-del Castillo, Carlos
    PANCREATOLOGY, 2022, 22 (02) : 264 - 269
  • [50] Prevalence and risk factors of extrapancreatic malignancies in a large cohort of patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas
    Larghi, A.
    Panic, N.
    Capurso, G.
    Leoncini, E.
    Arzani, D.
    Salvia, R.
    Del Chiaro, M.
    Frulloni, L.
    Arcidiacono, P. G.
    Zerbi, A.
    Manta, R.
    Fabbri, C.
    Ventrucci, M.
    Tarantino, I.
    Piciucchi, M.
    Carnuccio, A.
    Boggi, U.
    Costamagna, G.
    Delle Fave, G.
    Pezzilli, R.
    Bassi, C.
    Bulajic, M.
    Ricciardi, W.
    Boccia, S.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1907 - 1911